ClinicalTrials.gg
CompletedNCT01920568Updated Jan 16, 2017Results posted

A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors

A Phase 3 interventional study of Denosumab 70 mg/mL and Zoledronic acid 4 mg in Fractures, Bone, sponsored by GlaxoSmithKline. Completed at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
487
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Fractures, Bone with a site in China — 4 open to participants now, 5 under way, none of them phase 3. Fractures, Bone · China.

Enrollment
2nd of 20
487 · median 86
Started
2013
with 1 other
Phase 3
Only one
of the 23
Registered
4th of 23
by date
Lead sponsor
1 of 23
GlaxoSmithKline

Among the 23 studies in Fractures, Bone with a site in China, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2013, is the only one in phase 3, and was the 4th registered.

Fractures, Bone

725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.

Browse Fractures, Bone studies →

Open to participants now

4 of the 23 studies in Fractures, Bone with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 72 Fractures, Bone studies recruiting now, 36 (50%) set no upper age limit and 22 (31%) stop at 75 or younger; 17 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fractures, Bone with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors. The study is designed to provide data to a large global dataset of phase-III studies including breast cancer, prostate cancer, and all solid tumors, plus multiple myeloma, to support the regulatory approval for marketing and patient access to denosumab for the prevention of SREs in Chinese subjects with bone metastases from solid tumors. The primary objective of this study is to evaluate and compare the percent change from baseline to Week 13 in the bone marker urinary amino-terminal cross-linking telopeptide of type I collagen (uNTx) corrected for urine creatinine (uNTx/uCr) in subjects treated with denosumab to those treated with zoledronic acid. The study is designed to test the superiority of denosumab over zoledronic acid.

03

Conditions studied

  • Fractures, Bone

Browse trials for

Keywords

  • GSK2371746
  • Denosumab
  • China
  • skeletal-related events
  • bone metastases
  • bridging study
  • solid tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject understands the nature and purpose of this study and the study procedures, which have been explained by the Investigator or delegate, and subject has signed the written for the overall study. The subject must sign a separate written informed consent to be eligible for enrolment in the pharmacokinetic substudy.
  • Adult (aged >=18 years) of Asian ancestry with a or cytologically confirmed solid tumor. In addition, subjects who are enrolled at a center in mainland China or at an SFDA-certified center in Hong Kong including the approximately 33 subjects in the pharmacokinetic substudy must be of Chinese race, ancestry, or heritage. Subjects enrolled in other regions or countries, such as Taiwan and Singapore, or at a non-SFDA-certified center in Hong Kong, are not required to be of Chinese race or ancestry.
  • Current or prior documented radiographic evidence (i.e., x-ray, computer tomography [CT], or magnetic resonance imaging [MRI]) of at least 1 bone .
  • Female subjects of must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective , as defined below, during the study and for 6 months after end of study treatment. Women who report having a pregnancy during this study will be followed for birth outcomes. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows: An intrauterine device or intrauterine system with a documented failure rate of less than 1% per year; Male partner sterilization prior to the female subject's enrollment and the male is the sole sexual partner for that subject; the information on the male sterility can come from the site personnel's review of subject's medical records; medical examination of the subject and/or semen analysis; or interview with the subject on his medical history; complete abstinence from sexual intercourse for 14 days prior to first dose of study treatment, through the dosing period, and for at least 7 months after the last dose of study treatment; double-barrier contraception: male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository); implants of levonorgestrel or etonogestrel where not for this patient population or per local practice; injectable progesterone where not contraindicated for this patient population or per local practice; percutaneous contraceptive patches where not contraindicated for this patient population or per local practice; Oral contraceptives (either combined or progesterone only) where not contraindicated for this patient population or per local practice. Females of child bearing potential who do not have male partners as part of their preferred and usual lifestyle are not required to use contraception.
  • (ECOG) performance status of 0, 1, or 2 (refer protocol for details).
  • Adequate baseline organ function as defined by the following criteria: Serum (AST) \<=2.0 x (ULN); Serum alanine aminotransferase (ALT) \<=2.0 x ULN; Serum total \<=1.0 x ULN; (calculated using the Cockcroft-Gault formula) >=30 milliliter per minute (mL/min); serum calcium or albumin-adjusted serum calcium >=2.0 millimole per liter (mmol/L) (8.0 mg/dL) and \<=2.9 mmol/L (11.5 miligram per deciliter [mg/dL]). Subjects must not have taken supplemental calcium for at least 8 hours prior to collection of the blood sample for screening serum calcium determination.
  • of at least 6 months, in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that, in the opinion of the Investigator, could interfere with subject's safety, obtaining or compliance to the study procedures; The Investigator should consult the GSK Medical Monitor prior to enrolling a subject if s/he is unsure if a condition might interfere with the subject's safety or participation in this study.
  • Any prior treatment with intravenous (IV) or oral bisphosphonates.
  • Prior treatment with denosumab.
  • Planned radiation therapy or surgery to bone.
  • Known .
  • Prior history or current evidence of osteomyelitis or osteonecrosis of the jaws (ONJ), an active dental or jaw condition that requires oral surgery, non-healed dental or oral surgery, or planned invasive dental procedure over the course of the study.
  • Evidence of any of the following conditions per subject self report or medical chart review: any prior or current (other than the cancer under study in this protocol) with active disease within 3 years before randomization; unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); known infection with (HIV); active infection with or virus.
  • Pregnant women, women planning to become pregnant within 7 months after end of study treatment, and women who are breastfeeding. Women who are breast feeding should discontinue nursing prior to the first dose of study treatment and should refrain from nursing throughout the treatment period and for 7 months following their last dose of study treatment.
  • Male subjects unable or unwilling to use adequate methods during the study and for 6 months after end of study treatment should be excluded.
  • Subject is currently enrolled in another device or investigational product study, or has not completed at least 30 days, 5 half lives, or the duration of biological effect, whichever is longer, since ending such a study.
  • Known sensitivity to any of the investigational products or supplements to be administered during the study (i.e., zoledronic acid, mammalian derived products, calcium, or vitamin D).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
487 participants (actual)

Study arms

  • Experimental
    Denosumab 120 mg

    Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over \&gt;=15 minutes once every 4 weeks.

    Biological: Denosumab 70 mg/mL · Drug: Placebo IV · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement

  • Experimental
    Zoledronic acid 4 mg

    Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.

    Drug: Zoledronic acid 4 mg · Drug: Placebo SC · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement

Interventions

  • BiologicalDenosumab 70 mg/mL

    Drug page: Denosumab

    Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection

  • Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.

  • DrugPlacebo IV

    The placebo will consist of 1.7 mL 0.9% w/v sodium chloride

  • DrugPlacebo SC

    The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection

  • Dietary supplementCalcium supplement

    Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.

  • Dietary supplementVitamin D supplement

    Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.

06

What researchers measure

Primary outcomes

  1. Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)

    uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment (trt). uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Primary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Asian ancestry with bone metastases from solid tumors. BL value is the most recent, non-missing value prior to or on the 1st study trt dose date. Chg from BL is the value at Wk13 minus BL value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

    Time frame: Baseline (BL) and Week (Wk) 13

Secondary outcomes

  1. Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.

    uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Chinese ancestry with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

    Time frame: Baseline and Week 13

  2. Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.

    uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in breast cancer par. with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

    Time frame: Baseline and Week 13

  3. Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.

    Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Indicated visit minus Baseline value. Percent change from Baseline is the change from Baseline divided by Baseline value multiplied by 100.

    Time frame: Baseline and Week 13

  4. Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, non-fatal SAEs, fatal SAEs have been presented.

    Time frame: From start of IP through the Study Phase (49 weeks post-dose) (assessed up to 73 weeks)

  5. Number of Participants With Worst-case (WC) On-therapy Increase in the Indicated Clinical Chemistry Parameters From Baseline Grade to the Indicated Grade.

    Clinical chemistry parameters were measured at the Screening and Weeks 2, 5, 9, 13, 25, 37, and 53 visits. Clinical chemistry parameters measured on-study included albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium (Ca), creatinine, magnesium, and phosphorous (P) inorganic. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) was used for grading. Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

    Time frame: Baseline and up to last study-related visit (up to 53 weeks)

  6. Number of Participants With Worst-case On-therapy Increase in the Indicated Hematology Parameters From Baseline Grade to the Indicated Grade.

    Hematology parameters included hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell (WBC) count. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

    Time frame: Baseline and up to last study-related visit (up to 53 weeks)

  7. Number of Participants With Confirmed Anti-denosumab Antibody Formation at Day 1, Week 25 and Week 53.

    Anti-denosumab antibody formation was assessed at Day 1, Week 25 and Week 53. Binding antibody assay was used to assess number of participants with anti-denosumab antibody.

    Time frame: Day 1, Week 25 and Week 53

  8. Serum Concentration of Denosumab on Day 1, at Week 2, Week 5, Week 9, Week 13, Week 17, Week 19, Week 21, Week 25 and Week 49

    Blood samples were drawn on study Day 1, pre-dose; 4 hours, 24 hours, and at Week 2 (168 hours); then pre-dose at Week 5, Week 9, Week 13, Week 17, Week 19 (no dose), Week 21, Week 25, and Week 49.

    Time frame: Samples were collected at pre-dose (Day 1); 4 hours, 24 hours, 168 hours post-dose; pre-dose at Week 5, Week 9, Week 13, Week 17; Week 19 (at 336 hours); pre-dose at Week 21, Week 25, Week 49

07

Results

Posted Aug 25, 2016

Participant flow

The study consisted of three phases: Screening period , 49-week Double-blind treatment period and Follow-up period. The total participation time in the study was approximately 77 weeks.

Participant flow — Overall Study
MilestoneDenosumab 120 mgZoledronic Acid 4 mg
Started326159
Completed17575
Not completed15184
Withdrew: Adverse event278
Withdrew: Protocol violation53
Withdrew: Lost to follow-up22
Withdrew: Physician decision134
Withdrew: Withdrawal by subject7955
Withdrew: Death due to disease progression2512

Outcome measures

PrimaryPercent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)

uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment (trt). uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Primary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Asian ancestry with bone metastases from solid tumors. BL value is the most recent, non-missing value prior to or on the 1st study trt dose date. Chg from BL is the value at Wk13 minus BL value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

Time frame:
Baseline (BL) and Week (Wk) 13
Reported as:
Least squares mean · Percent change
Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)
Percent changeDenosumab 120 mgZoledronic Acid 4 mg
Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)-81.9 (-83.1 to -80.6)-75.2 (-77.6 to -72.5)
Statistical analysis
  • Denosumab 120 mg vs Zoledronic Acid 4 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -0.316 · 95% CI -0.440 to -0.192Primary analysis evaluated the log transformed chg from BL, i.e. log\[(Wk 13 uNTx/Cr) / (BL uNTx/Cr)\] by ANCOVA model with trt group as main effect and the stratification factor (breast cancer, yes or no) and log transformed BL value as covariates.
SecondaryPercentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.

uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Chinese ancestry with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

Time frame:
Baseline and Week 13
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.
Percent changeDenosumab 120 mgZoledronic Acid 4 mg
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.-82.2 (-83.4 to -80.8)-75.6 (-78.0 to -72.9)
Statistical analysis
  • Denosumab 120 mg vs Zoledronic Acid 4 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -0.316 · 95% CI -0.444 to -0.188Secondary analysis evaluated the log transformed chg from BL, ie log\[(Wk 13 uNTx/Cr)/(BL uNTx/Cr)\] by ANCOVA model with trt group as main effect and the stratification factor (Chinese participants, yes or no) and log transformed BL value
SecondaryPercentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.

uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in breast cancer par. with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.

Time frame:
Baseline and Week 13
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.
Percent changeDenosumab 120 mgZoledronic Acid 4 mg
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.-80.9 (-82.7 to -78.9)-72.4 (-76.1 to -68.2)
Statistical analysis
  • Denosumab 120 mg vs Zoledronic Acid 4 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -0.366 · 95% CI -0.539 to -0.193Secondary analysis evaluated the log transformed chg from BL, i.e. log\[(Wk 13 uNTx/Cr) / (BL uNTx/Cr)\] by ANCOVA model with trt group as main effect, stratification factor (Breast cancer, yes or no) and log transformed BL value as covariates.
SecondaryPercent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.

Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Indicated visit minus Baseline value. Percent change from Baseline is the change from Baseline divided by Baseline value multiplied by 100.

Time frame:
Baseline and Week 13
Reported as:
Median · Percent change
Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.
Percent changeDenosumab 120 mgZoledronic Acid 4 mg
Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.-36.8 (-96.2 to 93.8)-30.3 (-91.7 to 345.9)
SecondaryNumber of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, non-fatal SAEs, fatal SAEs have been presented.

Time frame:
From start of IP through the Study Phase (49 weeks post-dose) (assessed up to 73 weeks)
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)
ParticipantsDenosumab 120 mgZoledronic Acid 4 mg
Any AEs291145
Any SAEs4614
Any Fatal SAEs257
Any Non-Fatal SAEs257
SecondaryNumber of Participants With Worst-case (WC) On-therapy Increase in the Indicated Clinical Chemistry Parameters From Baseline Grade to the Indicated Grade.

Clinical chemistry parameters were measured at the Screening and Weeks 2, 5, 9, 13, 25, 37, and 53 visits. Clinical chemistry parameters measured on-study included albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium (Ca), creatinine, magnesium, and phosphorous (P) inorganic. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) was used for grading. Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

Time frame:
Baseline and up to last study-related visit (up to 53 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case (WC) On-therapy Increase in the Indicated Clinical Chemistry Parameters From Baseline Grade to the Indicated Grade.
ParticipantsDenosumab 120 mgZoledronic Acid 4 mg
Albumin (hyperalbuminemia), any grade, n=324, 15600
Albumin (hyperalbuminemia), WC G3, n=324, 15600
Albumin (hyperalbuminemia), WC G4, n=324, 15600
Albumin (hypoalbuminemia), any grade, n=324, 1564526
Albumin (hypoalbuminemia), WC G3, n=324, 15610
Albumin (hypoalbuminemia), WC G4, n=324, 15600
ALP, any grade, n=324, 1566731
ALP, WC G3, n=324, 15672
ALP, WC G4, n=324, 15600
ALT, any grade, n=324, 15613759
ALT, WC G3, n=324, 15674
ALT, WC G4, n=324, 15600
AST, any grade, n=323, 15511761
AST, WC G3, n=323, 15574
AST, WC G4, n=323, 15500
Total Bilirubin, any grade, n=324, 1553416
Total Bilirubin, WC G3, n=324, 15520
Total Bilirubin, WC G4, n=324, 15521
Calcium (hypercalcemia), any grade, n=324, 15643
Calcium (hypercalcemia), WC G3, n=324, 15600
Calcium (hypercalcemia), WC G4, n=324, 15601
Calcium (hypocalcemia), any grade, n=324,1567828
Calcium (hypocalcemia), WC G3, n=324, 15650
Calcium (hypocalcemia), WC G4, n=324, 15610
Creatinine, any grade, n=324, 1561613
Creatinine, WC G3, n=324, 15610
Creatinine, WC G4, n=324, 15600
Magnesium (hypermagnesemia), any grade, n=324, 15640
Magnesium (hypermagnesemia), WC G3, n=324, 15620
Magnesium (hypermagnesemia), WC G4, n=324, 15600
Magnesium (hypomagnesemia), any grade, n=324, 15682
Magnesium (hypomagnesemia), WC G3, n=324, 15600
Magnesium (hypomagnesemia), WC G4, n=324, 15600
P,inorganic(hyperphosphatemia),any grade,n=323,15600
P, inorganic (hyperphosphatemia),WC G3, n=323, 15600
P, inorganic (hyperphosphatemia),WC G4, n=323, 15600
P,inorganic(hypophosphatemia),any grade,n=323, 15612435
P, inorganic (hypophosphatemia),WC G3, n=323, 156359
P, inorganic (hypophosphatemia), WC G4, n=323, 15610
SecondaryNumber of Participants With Worst-case On-therapy Increase in the Indicated Hematology Parameters From Baseline Grade to the Indicated Grade.

Hematology parameters included hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell (WBC) count. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

Time frame:
Baseline and up to last study-related visit (up to 53 weeks)
Reported as:
Number · Participants
Number of Participants With Worst-case On-therapy Increase in the Indicated Hematology Parameters From Baseline Grade to the Indicated Grade.
ParticipantsDenosumab 120 mgZoledronic Acid 4 mg
Hemoglobin, any grade, n=316, 14713969
Hemoglobin, WC G3, n=316, 1472411
Hemoglobin, WC G4, n=316, 14700
Lymphocyte count decreased, any grade, n=315, 1477747
Lymphocyte count decreased, WC G3, n=315, 1472114
Lymphocyte count decreased, WC G4, n=315, 14711
Lymphocyte count increased, any grade, n=315, 14722
Lymphocyte count increased, WC G3, n=315, 14700
Lymphocyte count increased, WC G4, n=315, 14700
Platelet count, any grade, n=314, 1447748
Platelet count, WC G3, n=314, 14425
Platelet count, WC G4, n=314, 14421
Total neutrophils, any grade, n=315, 14712458
Total neutrophils, WC G3, n=315, 1474019
Total neutrophils, WC G4, n=315, 147128
WBC count, any grade, n=315, 14713878
WBC count, WC G3, n=315, 1472519
WBC count, WC G4, n=315, 14721
SecondaryNumber of Participants With Confirmed Anti-denosumab Antibody Formation at Day 1, Week 25 and Week 53.

Anti-denosumab antibody formation was assessed at Day 1, Week 25 and Week 53. Binding antibody assay was used to assess number of participants with anti-denosumab antibody.

Time frame:
Day 1, Week 25 and Week 53
Reported as:
Number · Participants
Number of Participants With Confirmed Anti-denosumab Antibody Formation at Day 1, Week 25 and Week 53.
ParticipantsDenosumab 120 mgZoledronic Acid 4 mg
Day 1, n = 326, 15800
Week 25, n = 256, 11500
Week 53, n = 180, 7600
SecondarySerum Concentration of Denosumab on Day 1, at Week 2, Week 5, Week 9, Week 13, Week 17, Week 19, Week 21, Week 25 and Week 49

Blood samples were drawn on study Day 1, pre-dose; 4 hours, 24 hours, and at Week 2 (168 hours); then pre-dose at Week 5, Week 9, Week 13, Week 17, Week 19 (no dose), Week 21, Week 25, and Week 49.

Time frame:
Samples were collected at pre-dose (Day 1); 4 hours, 24 hours, 168 hours post-dose; pre-dose at Week 5, Week 9, Week 13, Week 17; Week 19 (at 336 hours); pre-dose at Week 21, Week 25, Week 49
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Serum Concentration of Denosumab on Day 1, at Week 2, Week 5, Week 9, Week 13, Week 17, Week 19, Week 21, Week 25 and Week 49
micrograms per milliliter (µg/mL)Denosumab 120 mg
Day 1, Pre-dose, n=260 (0 to 0)
Day 1, 4 hours post-dose, n=26777.1 (574.2 to 1051.6)
Day 1, 24 hours post-dose, n=265521.6 (4744.2 to 6426.3)
Week 2, 168 hours post-dose, n=2611701.1 (10554.0 to 12973.0)
Week 5, Pre-dose, n=258658.1 (7631.1 to 9823.3)
Week 9, Pre-dose, n=2512086.4 (10284.9 to 14203.4)
Week 13, Pre-dose, n=2514867.5 (12515.5 to 17661.6)
Week 17, Pre-dose, n=2416543.3 (13871.8 to 19729.2)
Week 19, 336 hours, n=2220802.4 (16280.7 to 26579.9)
Week 21, Predose, n=2114508.0 (10907.0 to 19297.9)
Week 25, Predose, n=2216619.0 (13354.9 to 20681.0)
Week 49, Predose, n=1920029.2 (16282.7 to 24637.9)

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of IP through the Study Phase (49 weeks post-dose) (assessed up to 73 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 120 mg—46/326 (14.1%)268/326 (82.2%)
Zoledronic Acid 4 mg—14/159 (8.8%)136/159 (85.5%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventDenosumab 120 mgZoledronic Acid 4 mg
Respiratory failureRespiratory, thoracic and mediastinal disorders3/3262/159
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3262/159
Hepatic function abnormalHepatobiliary disorders0/3262/159
PneumoniaInfections and infestations3/3261/159
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3260/159
Disease progressionGeneral disorders3/3260/159
DyspnoeaRespiratory, thoracic and mediastinal disorders3/3260/159
DiarrhoeaGastrointestinal disorders1/3261/159
Urinary tract infectionInfections and infestations1/3261/159
Acute myocardial infarctionCardiac disorders0/3261/159
Most frequent other events
Showing 10 of 30
Most frequent other events
EventDenosumab 120 mgZoledronic Acid 4 mg
AnaemiaBlood and lymphatic system disorders81/32639/159
White blood cell count decreasedInvestigations68/32638/159
PyrexiaGeneral disorders41/32632/159
Decreased appetiteMetabolism and nutrition disorders61/32632/159
Neutrophil count decreasedInvestigations55/32630/159
Alanine aminotransferase increasedInvestigations56/32628/159
NauseaGastrointestinal disorders57/32623/159
LeukopeniaBlood and lymphatic system disorders55/32627/159
NeutropeniaBlood and lymphatic system disorders54/32625/159
Aspartate aminotransferase increasedInvestigations49/32626/159

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 120 mgZoledronic Acid 4 mgTotal
Mean54.0 ± 11.3653.6 ± 11.4553.9 ± 11.38
Gender
Gender(Participants)Denosumab 120 mgZoledronic Acid 4 mgTotal
Female222105327
Male10454158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 120 mgZoledronic Acid 4 mgTotal
Asian - East Asian Heritage312158470
Asian - South East Asian Heritage14115
08

Study locations

25 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510120, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510515, China
  • GSK Investigational Site
    Wuhan, Hubei 430030, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210002, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210009, China
  • GSK Investigational Site
    Changchun, Jilin 130012, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310003, China
  • GSK Investigational Site
    Beijing, 100021, China
  • GSK Investigational Site
    Beijing, 100034, China
  • GSK Investigational Site
    Beijing, 100036, China
  • GSK Investigational Site
    Beijing, 100071, China
  • GSK Investigational Site
    Fuzhou, 350001, China
  • GSK Investigational Site
    Hangzhou, 310016, China
  • GSK Investigational Site
    Harbin, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200032, China
  • GSK Investigational Site
    Shanghai, 200070, China
  • GSK Investigational Site
    Shanghai, 200080, China
  • GSK Investigational Site
    Shanghai, 200233, China
  • GSK Investigational Site
    Tianjin, 300060, China
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Taoyuan, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2013
First posted
Aug 12, 2013
Start
Aug 2013
Primary completionActual
Feb 2015
CompletionActual
Apr 2016
Results first posted
Aug 25, 2016
Last update
Jan 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01920568
Lead sponsor
GlaxoSmithKline
Collaborators
Amgen
Responsible party
Sponsor
First posted
Aug 12, 2013
Start date
Aug 2013
Primary completion
Feb 2015
Completion
Apr 2016
Results posted
Aug 25, 2016
Last update
Jan 16, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Denosumab · Zoledronic Acid

Start the discussion